Table 5. Distribution of activating KIR plus inhibitory KIR and their respective ligands in patients with and without ocular toxoplasmosis and its primary or recurrent manifestations.
| KIR - HLA ligands | Patients without toxoplasmic retinochoroiditis (n = 149) | Patients with toxoplasmic retinochoroiditis (n = 148) | Patients with primary manifestation (n = 120) | Patients with recurrent manifestation (n = 28) |
|---|---|---|---|---|
| N (%) | N (%) | N (%) | N (%) | |
| KIR-C1 | ||||
| 2DS2+/2DL2−/C1+ | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| 2DS2−/2DL2+/C1+ | 33 (22.1) | 41 (27.7) | 30 (25.0) | 11 (39.3) |
| 2DS2+/2DL3−/C1+ | 9 (6.0) | 12 (8.1) | 10 (8.3) | 2 (7.1) |
| 2DS2−/2DL3+/C1+ | 66 (44.3) | 67 (45.3) | 54 (54.0) | 13 (46.4) |
| 2DS2+/2DL2−/2DL3−/C1+ | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| 2DS2−/2DL2−/2DL3+/C1+ | 33 (22.1) | 26 (17.6) | 24 (20.0) | 2 (7.1) |
| 2DS2+/2DL2−/2DL3+/C1+ | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| 2DS2−/2DL2+/2DL3+/C1+ | 33 (22.1) | 41 (27.1) | 30 (25.0) | 11 (39.3) |
| 2DS2+/2DL2+/2DL3-/C1+ | 9 (6.0) | 12 (8.1) | 10 (8.3) | 2 (7.1) |
| 2DS2+/2DL2+/2DL3+/C1+ | 13 (8.7) | 4 (2.7) | 4 (3.3) | 0 (0.0) |
| KIR-C2 | ||||
| 2DS1+/2DL1−/C2+ | 0 (0.0) | 2 (1.4) | 2 (1.7) | 0 (0.0) |
| 2DS1−/2DL1+/C2+ | 74 (49.7) | 67 (45.3) | 56 (46.7) | 11 (39.3) |
| 2DS1+/2DL1+/C2+ | 49 (32.9) | 54 (36.5) | 43 (35.8) | 11 (39.3) |
| KIR-BW4-80Ile | ||||
| 3DS1+/3DL1+/BW4−80Ile+ | 32 (21.5) | 53 (35.8) | 42 (35.0) | 11 (39.3) |
| 3DS1+/3DL1−/BW4−80Ile+ | 1 (0.7) | 3 (2.0) | 3 (2.5) | 0 (0.0) |
| 3DS1−/3DL1+/BW4−80Ile+ | 71 (47.7)a,b | 48 (32.4)a | 45 (37.5)c | 3 (10.7)b,c |
aOR = 0.52; CI = 0.32–0.84; P = 0.009; Pc = 0.02 (Patients without ocular toxoplasmosis vs. Patientes with ocular toxoplasmosis).
bOR = 0.13; CI = 0.03–0.45; P = 0.0003; Pc = 0.0009 (Patients without ocular toxoplasmosis vs. Patientes with recurrent manifestation).
cOR = 0.20; CI = 0.05–0.70; P = 0.006; Pc = 0.01 (Patients with primary manifestation vs. Patients with recurrent manifestation).